



Certificate of analysis

SFC279-03-02

Operator: Alison McBride

Date: 11/01/2016

Supervisor: Zam Cader

Date: 01/11/2016

Signature:



A handwritten signature in blue ink that reads "Zam Cader". The signature is written in a cursive, flowing style.

Source of fibroblasts and reprogramming information


- SF279 from Glostrup Hospital, Denmark
11/06/2015
- Reprogrammed at UOXF Z
- Reprogrammed on 18/08/2015 at passage 4
- Cytotune v2 WP3 SOP10

Viability post-thaw and Morphology according to SOP19 passage 14

- Cell count immediately post-thaw 1.88×10^6
- Viability immediately post-thaw 89%
- Photo at 24h and low density at day 4 post-thaw (scale bar = $100\mu\text{m}$):



Sendai clearance: according to WP3 SOP15 undetectable at passage 14



Product sizes: Actin 92bp; SeV 181bp; SeV KOS 528bp; SeV-Myc 532bp; SeV-Klf 410bp;

Mycoplasma Test:

According to MycoAlert Lonza LT07-318 undetectable at passage 14

Sample	Passage Number	Initials	Reading 1	Reading 2	Ratio/Status
+ ve control			46	1691	36.76
- ve control			61	16	0.26
SFC279-03-02	p14	AM	40	16	0.40

Results:


Ratio **0 - 0.999** negative for mycoplasma

Ratio **1 – 1.3** Borderline Result (retest required)


Ratio above **1.3** positive for mycoplasma

Flow cytometric analysis according to WP3 SOP 20 and 21 passage 14

Tra-1-60:



NANOG:



SNP analysis

according to WP3 SOP Preparation of DNA
and RNA samples for Illumina arrays

- Passage 14
- Identity to parent fibroblasts confirmed
- Karyotype abnormalities: none detected
- For details and raw data see StemDB